Sanofi India posts 27% growth in operating profits in Q1 2025

Standalone profit from operations for the quarter were Rs. 162 crores

Sanofi Consumer Healthcare India Q1 PAT up 12.9%

The Q1 2025 also witnessed a successful launch of Allegra D

Sanofi India MD Rodolfo Hrosz to step down on April 30

The board of directors accepted Hrosz’s resignation and expressed appreciation for his significant contributions during his tenure

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD

Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)

Sanofi India declares 8% growth in net sales for Q4-2024

Standalone profit from operations for Q4-2024 were Rs. 108 crore

Teva and Sanofi present new outcome from Phase 2b study of duvakitug

Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025

Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

No safety signals related to the vaccine candidate were identified

Sanofi acquires rights to develop and commercialize Aficamten in Greater China

In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China

Sanofi invests €40 million to strengthen antibody bioproduction in France

Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype